Sign in

Trial result ·

Quality of life outcomes with a new sustained‑release pregabalin in a phase 3 trial of peripheral neuropathic pain.

Written based on 1 research study on PubMed, searched on 15 Nov 2026.

What was studied

This trial tested a new slow-release form of the drug pregabalin, called YHD1119. It is taken once a day. It was compared with the usual quick-release pregabalin. That form is taken more than once a day. The people were Korean adults with nerve pain. Their pain came from diabetic peripheral neuropathy or postherpetic neuralgia. People were put into groups by chance, and nobody knew who got which form. Each group took its drug for 12 weeks. This report looks at how people felt about their daily life and health.

What they found

In all, 296 people were counted in this report. Scores for body health rose in both groups by a similar amount. Scores for mind health also rose, with no clear gap between groups. Sleep got better in both groups. At week 12, the groups did not differ in sleep. People and their doctors were also asked if things had changed for the better. The share who said yes was alike in both groups.

What it means for patients

The authors say the once-a-day form gave daily life results like the quick-release form. This held for general health, sleep and the overall sense of change. They see the new form as a handy option that keeps the benefit. Its main gain is that people take just one dose each day.

Why it is not certain yet

This report looked only at daily life and health scores. Results cover only 12 weeks of treatment. Only Korean adults with these kinds of nerve pain took part. Only people who kept to the study plan were counted. The abstract does not give side effect results.

Source

Quality of life outcomes with a new sustained‑release pregabalin in a phase 3 trial of peripheral neuropathic pain.

PubMed · PMID 42622433

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Diabetic neuropathy publications